Bavituximab: Additional Phase II data

Additional data from an open-label, international Phase II trial in 83 evaluable patients with previously untreated stage IIIb/IV NSCLC showed that once-weekly 3 mg/kg bavituximab plus carboplatin and paclitaxel led to a median OS of 14 months. Peregrine did not disclose the median OS for patients receiving carboplatin and paclitaxel alone, but said that there was "not a meaningful enough difference in survival between the two arms of the trial that would support the advancement of this combination." Last year, Peregrine reported that bavituximab plus chemotherapy led to an estimated median PFS of 5.8 months vs. 4.6 months for chemotherapy alone. Additionally, bavituximab plus chemotherapy led to an ORR of 32% vs. 31% for chemotherapy alone (see BioCentury, Dec. 12, 2011 & March 19, 2012). ...